Antimyelin antibodies as predictors of disability after clinically isolated syndrome

International Journal of Neuroscience

Volumn 124, Issue 8, 2014, Pages 567-572

  Findling, Oliver ^a   Durot, Isabelle ^a   Weck, Anja ^a   Jung, Simon ^a   Kamm, Christian P ^a   Greeve, Isabell ^b   Mattle, Heinrich P ^a   Sellner, Johann ^c,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Christian Doppler Klinik   (Austria)

Author keywords

Autoimmunity; Biomarker; Multiple sclerosis; Prognosis

Indexed keywords

IMMUNOMODULATING AGENT; MYELIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; SERUM; SEX DIFFERENCE; SWITZERLAND; WESTERN BLOTTING; BLOOD; DEMYELINATING DISEASES; HEALTH SURVEY; METABOLISM; MIDDLE AGED; MYELIN SHEATH; PREDICTIVE VALUE; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; DEMYELINATING DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELIN SHEATH; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SWITZERLAND; YOUNG ADULT;

EID: 84894239357     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.869221     Document Type: Article

References (32)

1. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476(7359): 214-9
2. Sellner J, Kraus J, Awad A, et al. The increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors. Autoimmun Rev 2011; 10(8): 495-502
3. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4(5): 281-8
4. Sellner J, Schirmer L, Hemmer B, Mühlau M. The radiologically isolated syndrome: Take action when the unexpected is uncovered? J Neurol 2010; 257(10): 1602-11
5. Sellner J, Weber MS, Vollmar P, et al. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: Enthusiasm lost too soon? CNS Neurosci Ther 2010; 16(6): 362-73
6. Von Büdingen H-C, Gulati M, Kuenzle S, et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce' oligoclonal bands'. J Neuroimmunol 2010; 218(1-2): 134-9
7. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128(Pt 7): 1667-76
8. Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE. 2008; 3(7): E2559
9. Gabibov AG, Belogurov AA Jr, Lomakin YA, et al. Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. The FASEB J 2011; 25(12): 4211-21
10. Wang H, Munger KL, Reindl M, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008; 71(15): 1142-1146
11. Selter RC, Brilot F, Grummel V, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010; 74(21): 1711-1715
12. Kerlero de Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990; 55(2): 583-7
13. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349(2): 139-45
14. Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord 2012; 5(3): 147-59
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'.Ann Neurol 2005; 58(6): 840-6
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52
17. Greeve I, Sellner J, Lauterburg T, et al. Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurol Scand 2007; 116(4): 207-10
18. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346(3): 158-64
19. Kuhle J, Lindberg RLP, Regeniter A, et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007; 254(2): 160-8
20. Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11(4): 492-4
21. Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006; 77(6): 739-42
22. Tomassini V, De Giglio L, Reindl M, et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007; 13(9): 1086-94
23. Pittock SJ, Reindl M, Achenbach S, et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: Frequency, stability and clinicopathologic correlations. Mult Scler 2007; 13(1): 7-16
24. Menge T, von Büdingen H-C, Lalive PH, Genain CP. Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol 2007; 37(11): 3229-39
25. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103(50): 19057-62
26. Menge T, Lalive PH, von Büdingen HC, Genain CP. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 2011; 8: 161
27. O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognizemyelin oligodendrocyte glycoprotein. J Immunol 2005; 175(3): 1974-82
28. Klawiter EC, Piccio L, Lyons J-A, et al. Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch Neurol 2010; 67(9): 1102-1108
29. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66(6): 833-42
30. Lalive PH, Häusler MG, Maurey H, et al. Highly reactive antimyelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011; 17(3): 297-302
31. Vogt MHJ, Teunissen CE, Iacobaeus E, et al. Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80(10): 1110-1115
32. Lim ET, Petzold A, Leary SM, et al. Serum S100B in primary progressive multiple sclerosis patients treated with interferonbeta-1a. J Neg Results Biomed 2004; 3: 4